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Patricia Halfon1*, Yves Eggli2, Anne Decollogny2 and Erol Seker2Abstract
Background: Pharmacy-based case mix measures are an alternative source of information to the relatively scarce
outpatient diagnoses data. But most published tools use national drug nomenclatures and offer no head-to-head
comparisons between drugs-related and diagnoses-based categories. The objective of the study was to test the
accuracy of drugs-based morbidity groups derived from the World Health Organization Anatomical Therapeutic
Chemical Classification of drugs by checking them against diagnoses-based groups.
Methods: We compared drugs-based categories with their diagnoses-based analogues using anonymous data on
108,915 individuals insured with one of four companies. They were followed throughout 2005 and 2006 and
hospitalized at least once during this period. The agreement between the two approaches was measured by
weighted kappa coefficients. The reproducibility of the drugs-based morbidity measure over the 2 years was
assessed for all enrollees.
Results: Eighty percent used a drug associated with at least one of the 60 morbidity categories derived from
drugs dispensation. After accounting for inpatient under-coding, fifteen conditions agreed sufficiently with their
diagnoses-based counterparts to be considered alternative strategies to diagnoses. In addition, they exhibited
good reproducibility and allowed prevalence estimates in accordance with national estimates. For 22 conditions,
drugs-based information identified accurately a subset of the population defined by diagnoses.
Conclusions: Most categories provide insurers with health status information that could be exploited for healthcare
expenditure prediction or ambulatory cost control, especially when ambulatory diagnoses are not available. However,
due to insufficient concordance with their diagnoses-based analogues, their use for morbidity indicators is limited.
Keywords: Case mix, Pharmacy data, Ambulatory care, Drug utilization, Kappa coefficientsBackground
Building health indicators, managing health care and pre-
vention, and adjusting for insurers’ risks require the as-
sessment of morbidity burdens [1]. Demographic variables
do not account sufficiently for the discrepancy in health
service use and costs, overestimating cost variations be-
tween care providers and misidentifying outliers [2,3].
Most developed countries have minimal data sets on
inpatient morbidity and causes of death. Outpatient
morbidity information is scarcer except for cancer registers* Correspondence: patricia.halfon@chuv.ch
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reproduction in any medium, provided the orand contagious infections, which are subject to mandatory
declaration. National health surveys have been conducted
to estimate the prevalence of chronic illnesses but such
expensive and time-consuming studies are generally not
feasible on an ongoing basis [4,5]. Although the increased
use of electronic medical records (EMR) by primary physi-
cians has the potential to collect clinical information in
large populations, the identification of a particular dis-
ease within an EMR often remains far from straightfor-
ward [6,7].
Current patient classification systems are mainly
based on diagnoses information. In the USA, Medicare
and Medicaid databases and some private health insur-
ance or maintenance organizations routinely recordLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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countries, such records are missing mainly because data
collection is time-consuming, costly and not always
reliable [8,9].
Thence the growing interest in measures based on drug
prescription data, often routinely collected by insurers;
they may also provide information on well-controlled
diseases, which are frequently under-declared by physi-
cians [10,11].
Most medication-based classification systems are de-
rived from the chronic disease score (CDS) developed by
Von Korff et al., with a fair prediction of hospitalization,
mortality, the number of ambulatory visits and costs
[12-14]. Improvements now include a wider range of
drugs, new scores, and extended application to various
populations (pediatric, Medicare and Medicaid, veterans,
European countries) [15-18]. For example the “Rxrisk”
model developed by Fishmann included 55 therapeutic
categories. It was designed to predict future health costs
and thus restricted to chronic diseases [19].
Only a few studies on selected populations have
checked criterion validity by comparing drugs categories
head-to-head with their diagnoses-based analogues [18].
As measured by the Kappa coefficient (< 0.4), 40% of
the “Rxrisk” categories seldom matched with their ICD-
9-CM based counterparts. Drug rates provided a valid
estimation of diagnosed and treated prevalence for only
few medical conditions [20,21].
Many drugs- related classification systems were built
on national drug nomenclatures [14,17]. However, since
indications for certain agents differ depending on how
they are administered, names alone do not adequately
express a condition. Pharmacy-based models should be
regularly updated and validated to verify that they are
not sensitive to practice variations.
The overall aim of our work was to develop a clinically
relevant drugs-based case mix measure, derived from the
WHO Anatomical Therapeutic Chemical (ATC) classifi-
cation of drugs [22]. Diagnoses information not being
available for ambulatory care, we limited the accuracy
assessment of disease detection to the hospitalized popu-
lation. Testing the performance of drugs-based patient
classification systems to predict ambulatory resources
or health outcomes was beyond the scope of our work.
Methods
Setting
Our study is an observational study based on routine
data from four Swiss health insurers on approximately
2.0 million insured enrollees of whom 1.7 million were
followed in 2005 and 2006. Among the latter, all insured
hospitalized at least once in a Swiss hospital were retained.
Data were collected with the support of the Swiss Federal
Office of Public Health [23]. Dispensed medication wasidentified by a national product code (pharmacode). As
in Switzerland pharmacists systematically send drugs codes
and dispensation dates to insurers for billing purposes,
we expect only minimal inaccuracies in those data. All
Swiss citizens are covered by compulsory insurance
and thus have unrestricted access to drugs. Few drugs
dispensed in outpatient hospital settings (e.g. anti-neoplastic)
were not in the database. Pharmacy data were linked to
corresponding hospital diagnoses codes (ICD-10) [24]
via the anonymous linkage code procedure by the Swiss
Federal Statistical Office (SFSO); only a sequential num-
ber was delivered [25]. Hospital data supplied by the
Federal Statistical Office (inpatient diagnoses) are pub-
licly available. Insurers’ data (dispensed drugs) are not
publicly available and were supplied only for the re-
search project supported by the Federal Public Health
Office, with the prerequisite of using the anonymous
linkage code procedure of the Federal Statistical Office.
All data were anonymous and did not include any element,
which might allow identifying a single person (no birth
date or ZIP codes for instance) [26]. More than 99% of
the insured had a corresponding anonymous linkage
code in the hospital SFSO data base. As in most other
developed countries, only diagnoses which had an im-
pact on the treatment of the patient were collected [27].
The space for recording diagnoses was limited to ten
codes. These medical records were mainly used for
epidemiological studies and hospital resources alloca-
tion (Diagnosis Related Groups). Several cantons allow
physicians to dispense drugs to patients directly (self-
dispensation). In such cases, information on dispensed
drugs was limited to their costs. To avoid information
bias, patients for whom self-dispensation represented
more than 5% of drugs costs were excluded. For chronic
diseases, all dispensed drugs were considered regardless
of the dispensing and hospitalization dates, while for
acute diseases only drugs dispensed two months before
a hospital admission or after discharge were kept. In the
event of several hospital stays of a same patient, all diag-
noses and drugs related to each hospitalization were kept
but the patient was considered as only one observation.
Assigning diagnoses and drugs to morbidity groups
Diagnoses consisted of over 16,000 ICD10 codes, too many
to be manageable. Therefore, in a first step, they were
grouped under the 130 categories of the International
Shortlist for Hospital Morbidity Tabulation (ISHMT)
recommended by the World Health Organization [24].
Diagnoses groups which usually do not require a specific
drug treatment (trauma, surgical or obstetrical conditions,
congenital malformations, and unspecified morbidities
or symptoms) were excluded (Additional file 1). Mor-
bidity groups were deduced from main and secondary
diagnoses coded in hospital medical records.
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cation system, after the exclusion of other pharmaceutical
products (dressings, homeopathy, herbal medicine, etc.).
We mainly used the therapeutic subgroups (2nd level of
the classification, e.g. A10 = anti-diabetic drugs), but a
higher level of classification was sometimes required to
identify a specific disease (e.g. therapy against HIV disease).
Subgroups that could not be matched with any morbidity
categories (blood products, anesthesia, etc.) were not taken
into account (Additional file 1).
We identified all diagnostic categories assignable to one
therapeutic subgroup. Most other diagnostic categories
were subdivided to match therapeutic subgroups. In other
cases, we grouped diagnostic categories requiring similar
treatment. For certain conditions, we combined scattered
ICD-10 codes corresponding to similar treatments (e.g.
bacterial infection or thrombo-embolic diseases). Face
validity of each morbidity category inferred from drug
information was ensured by thorough reviews conducted
by a skilled physician (PH) and a skilled pharmacist (AD)
as regards the clinical homogeneity of the condition and
the labeled use of the drug.Table 1 Agreement between diseases screened by drugs
and hospital coded diagnoses
Hospital diagnoses
Condition
present
Condition
absent
Drug data Condition present a b Q
Condition absent c d Q´
P P´ 1.0Accuracy of morbidity groups identification
An algorithm identifying subjects with different condi-
tions or diseases may be seen as a diagnostic test, and is
generally assessed by the four estimates of diagnostic
accuracy: sensitivity, specificity, positive and negative
predictive values. These measures establish one of the
classification procedures (here: morbidity categories based
on inpatient ICD-10 codes) as a true gold standard. Yet
we know that co-morbidities are often not recorded in
hospital minimal data sets, especially if their impact on
resource use is weak, or for patients with a more serious
illness, where the severity of the condition and compli-
cations take precedence over chronic conditions in cod-
ing [28,29]. We thus focused mainly on the degree of
agreement between the two morbidity classifications.
To ensure the identification of chronic diseases over
both 2005 and 2006, a test-retest procedure was applied
to all subjects classified in at least one drug-based cat-
egory in 2005.
We computed the prevalence in 2005 of morbidities
estimated from ambulatory drugs dispensation for all
insured. Underestimation of cases due to the removal of
subjects receiving medication directly from their phys-
ician was corrected via the assumption that morbidity
distribution in this population was similar to the rest.
For comparisons against published estimates (external
data), crude rates were standardized using gender and a
distribution by five-year age categories of the Swiss popu-
lation in 2005. When reference rates were available only
for a specific population restricted to categories definedby age or sex, direct standardization of rates used only
groups of this particular population.
Statistical analysis
The results according to drug and diagnoses based infor-
mation may be arranged in a four cells table with pro-
portions as shown in Table 1.
The Kappa coefficient (Kc), described by Cohen, is
commonly used to assess agreement between two rat-
ings [30]. It is obtained from the proportion of observed
agreement, o = (a + d) and the expected agreement,
e = (a + c) (a + b) + (c + d) (b + d), as follows.
Kc ¼ o−eð Þ= 1−eð Þ
Zero indicates only chance agreement, 1 indicates
complete agreement beyond chance.
One limitation of Kc is that the measure ignores the
relative utility of false positives (b) versus false negatives
(c). To deal with this problem we proposed the weighted
Kappa coefficient Kw, where the weight indicates the
relative importance of false negatives versus false posi-
tives [31,32]. K0 (weight = 0) is recommended if expected
false negatives (PQ’) have zero utility; K1 (weight = 1) if
expected false positives (P’Q) have zero utility (see
Additional file 1 for details).
Use of drug-based morbidities for measuring health
care indicators was grounded on the values of the three
Kappas, Κc, Κ0, Κ1. Agreement between illnesses screened
by delivered drugs and inpatient-coded diagnoses must be
high to compare similar clinical situations. As suggested
by Landis and Koch, we considered that a Kc over 0.4
describes a minimal level of agreement [33]. We relaxed
this criterion if one of the weighted Kappas (K0 or K1) was
respectively greater than 0.4 in the two following situa-
tions: existing alternatives to drug treatment explained
a substantial proportion of false negatives (K0 >0.4 is
required), or the high risk of under-reporting a non-
severe morbidity explained a substantial proportion of
false positives (K1 > 0.4 is required). We analyzed false posi-
tives and negatives in order to locate the potential errors in
the two screening methods and - if possible – to improve
the screening algorithm based on drug information.
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chose to present the findings according to three poten-
tial fields of application of a heath status routine meas-
ure: morbidity indicators, ambulatory care cost control,
and health insurers’ risk adjustment (Table 2, col. use).
Morbidity indicators i.e., incidence or prevalence mea-
sures, (M in Table 2), require accurate disease detection,
with KC greater than 0.4, or K1 > 0.4, if false positives
are explained by under-coded diagnoses. However, cri-
teria can be relaxed to K0 or K1 > 0.2 for ambulatory
cost control or risk adjustment (C and R in Table 2),
since it is better to detect some morbidity rather than
none. Note that only chronic diseases are relevant to
insurers’ risk adjustment, given that the aim of that
procedure is to forecast costs. Finally, despite satisfac-
tory concordance, caution should be exercised when
considering conditions for which the indication of drugs
might be uncertain or is prone to practice variations
(Table 2, footnote c).
Year-to-year category stability was measured by the Κ1
coefficient. We expected chronic diseases detected in
2005 to also be detected in 2006, as reflected by a high
K1, i.e. >0.6 [33].
Cohen Kappa coefficients were given with a 95% confi-
dence interval [34].
Results
Table 3 lists morbidity groups with corresponding ICD-
10 and ATC codes. Eighteen diagnostic categories of the
ICD shortlist were left unmodified, and 31 were subdi-
vided to fit drug categories. Five morbidity groups were
built by grouping diagnostic categories, and six by group-
ing subcategories. Thus we obtained 60 morbidity groups
derivable from drugs dispensation. Morbidity groups were
attributed independently to all insured inpatients from
coded diagnoses (Table 3, ICD-10 column) and dispensed
drugs (Table 3, ATC codes).
The studied population included 108,915 insured enrol-
lees followed throughout 2005 and 2006; they were hospi-
talized at least once, and did not obtain over 5% of their
drugs via self- dispensation by a physician. Sixty four
percent of hospitalizations (N = 70,083) were classified
in at least one of the morbidity groups listed in Table 3
(average number of categories: 2.75). Eighty percent
(N = 86,915) took a drug associated with at least one
of these morbidity categories (average number of cat-
egories: 6.08). The mean age of the studied population
was 53.1 years (SD 22.5), with a 44% proportion of
men. Results for the 60 morbidity groups identified by
drugs or hospitals diagnoses are given in Table 2. All
Kc confidence intervals were narrow, i.e. not more than
1% above or below the estimates.
Five morbidity categories (transplant, diabetes, HIV
disease, hypertension and thyroid disorders) had a Kcexceeding 0.4, justifying the use of drug-based informa-
tion for morbidity indicators, cost control and risk
adjustment purposes. As most antihypertensive agents
are also recommended for heart failure, we combined
those two categories and obtained an enhanced agree-
ment between drugs and diagnoses.
Eight conditions can be treated without drugs (false
negatives), justifying a K0 greater than 0.4: no indication
of long-term treatment for progressive multiple sclerosis,
non-nutritional anemia, or chronic hepatitis, surgery for
ischemic heart disease, conduction disorders, or malig-
nant disease, and the psychosocial treatment of alcohol
or opioid abuse. Considering chronic renal failure and
chemotherapy as proxies of non-nutritional anemia (usual
complications), we observed a significantly increased
K0 (0.63), suggesting a possible under-coding of the
condition. All these conditions identified from drug
dispensations correspond to actual morbidities, justify-
ing their use for cost control and risk adjustment.
Five conditions were related to obvious under-coded
diagnoses with a K1 over 0.4: glaucoma, hyperlipidemia,
functional digestive disorders, prostate hyperplasia, and
osteoporosis. These conditions are often not coded be-
cause they seldom merit hospital treatment. We also
found evidence of under-coding for four other morbid-
ities with K1 >0.4, as shown by the improvement of K0
to fair values when the screen is restricted to those
subjects who receive the most treatment, and were
thus more likely to feature in the hospital data. Indeed, K0
increased from 0.18 to 0.36 for mood disorders when the
screen was restricted to patients taking three classes of
psychotropic drugs; from 0.25 to 0.46 for reactive airway
disease (RAD) when screening criteria required inhaled
and systemic corticoids; from 0.31 to 0.43 for Alzheimer’s
disease when criteria included memantine use (indicated
for more severe impairments); from 0.25 to 0.33 for in-
flammatory bowel diseases (IBD) when criteria included
systemic corticoid or immune-suppressors in addition to
the tracer drugs.
Three conditions were difficult to detect because some
tracer drugs can be prescribed for other diseases, explain-
ing false positives and the use of K1 value as criteria. The
following refinements of the algorithms significantly
improved Kc values without excessively lowering K1 values
(see Table 2): removing the association of an anti-
cholinergic medication and a neuroleptic from the screen
of Parkinson’s disease (treatment of neuroleptic-induced
extra-pyramidal symptoms); removing the association of
neuroleptic and anti-cholinesterasic drugs from the screen
of psychotic disorders (treatment of behavior disorders
of dementia); removing the association of opioids with
gabapentine or pregabaline from the screen of epilepsy
(treatment of chronic pain). There was also some evi-
dence of under-coding of epilepsy, because Ko increased
Table 2 Accuracy of disease detection through drugs prescription among hospitalized patients (N = 108,915)
Morbidity group Diagnosed condition Screened by drug Sensitivity Specificity Kc
a K0
a K1
a Useb
With KC > 0.4
Transplant 467 601 0.82 1 0.71 (0.63) (0.82) M, C, R
Diabetes mellitus 8,171 8,114 0.71 0 0.70 (0.70) (0.69) M, C, R
HIV disease 413 372 0.60 1 0.63 (0.67) (0.60) M, C, R
Hypertensive disease 22,307 34,680 0.77 0 0.49 (0.37) (0.67)
Alternative refinement:
Hypertension and heart failure 23,886 35,954 0.78 0 0.51 (0.39) (0.68) M, C, R
Thyroid disorders 3,179 2,993 0.40 0 0.40 (0.41) (0.38) M, C, R
With K0 >0.4 and alternatives to pharmacological treatment
Multiple sclerosis 444 115 0.20 1 (0.32) 0.78 (0.20) C, R
Abuse of alcohol 4,584 619 0.09 1 (0.16) 0.68 (0.09) C, R
Ischemic heart disease 10,691 4,537 0.26 0 (0.33) 0.56 (0.23) C, R
Conduction disorders and cardiac arrhythmias 8,297 2,512 0.18 0 (0.26) 0.56 (0.16) C, R
Malignant neoplasms 7,528 3,757 0.29 0 (0.36) 0.54 (0.26) C, R
Abuse of opioid 1,131 45 0.02 1 (0.04) 0.51 (0.02) C, R
Hepatitis B or C 885 90 0.05 1 (0.09) 0.50 (0.05) C, R
Non-nutritional anaemia 6,114 642 0.05 1 (0.08) 0.41 (0.04)
Including those of end stage renal disease and due to chemotherapy 8,868 642 0.05 1 (0.08) 0.63 (0.04) C, R
With K1 > 0.4
Obvious under-coded diagnoses
Glaucoma 431 4167 0.70 0 (0.13) (0.07) 0.69 M, C, R
Hyperlipidemia 8,052 18,050 0.71 0 (0.38) (0.26) 0.65 M, C, R
Functional digestive disorders 1,275 27,846 0.63 0 (0.04) (0.02) 0.50 c
Hyperplasia of prostate 2,793 7,816 0.52 0 (0.26) (0.17) 0.49 M, C, R
Osteoporosis 2,443 4,765 0.49 0 (0.31) (0.23) 0.46 M, C, R
Signs of under-coded diagnoses
Mood disorders 6,649 19,624 0.68 0 (0.29) (0.18) 0.61 M, C, R
Reactive airway disease 6,045 11,960 0.58 0 (0.36) (0.25) 0.53 M, C, R
Alzheimer’s disease 844 1,307 0.48 0 (0.37) (0.31) 0.48 M, C, R
Crohn’s disease and ulcerative colitis 433 824 0.48 0 (0.33) (0.25) 0.48 M, C, R
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Table 2 Accuracy of disease detection through drugs prescription among hospitalized patients (N = 108,915) (Continued)
Multiple diagnoses indication of tracer drugs
Parkinson’s disease 914 2,219 0.67 0.99 (0.38) (0.27) 0.66
Alternative refinement
w/o anti-psychotic 914 1,739 0.65 0.99 0.44 (0.37) 0.64 M, C, R
Schizophrenia and other disorders 1,911 6,439 0.67 0.95 (0.29) (0.18) 0.64
Alternative refinement
w/o anti-cholinesterasic 1,911 5,985 0.66 0.96 (0.30) (0.20) 0.64 C, R
Epilepsy 1,656 5,727 0.54 0.96 (0.23) (0.14) 0.52
Alternative refinement
w/o chronic pain drugs 1,656 4,260 0.52 0.97 (0.28) (0.19) 0.50 C, R
Prophylactic treatment
Thrombo-embolic risk or disease 6,122 29,427 0.72 0.76 (0.18) (0.10) 0.61
if including thrombogenic cardiac diseases 17,804 29,427 0.73 0.82 0.45 (0.33) 0.63 M, C, R
Diseases of esophagus, peptic ulcer 3,805 31,331 0.72 0.73 (0.11) (0.05) 0.60 c
With all K values < 0.4
Acute diseases with time limited treatment, minor or rare conditions as inpatients
Migraine 601 1,771 0.29 0.99 (0.14) (0.09) 0.28 C
Vertigo 623 2,084 0.29 0.98 (0.13) (0.08) 0.28 c
Bacterial infection or septicemia 10,433 41,704 0.58 0.64 (0.13) (0.05) 0.32 c
Eye inflammation 467 6,827 0.33 0.94 (0.04) (0.02) 0.29 C
Dermatitis 1,091 14,461 0.33 0.87 (0.03) (0.02) 0.23 C , R
Mycosis 988 16,971 0.36 0.85 (0.03) (0.01) 0.25 C
Other diseases of upper respiratory tract – allergy 466 9,917 0.31 0.91 (0.02) (0.01) 0.24 C
Disorders of external ear 71 2,070 0.27 0.98 (0.02) (0.01) 0.25 C
Parasitosis 61 1,984 0.26 0.98 (0.01) (0.01) 0.25 C
Other acute upper respiratory infections 856 32,259 0.50 0.71 (0.01) (0.01) 0.28 c
Acne 72 2,774 0.25 0.97 (0.01) (0.01) 0.23 C , R
Psoriasis 466 1,188 0.35 0.99 (0.19) (0.13) 0.34 C , R
Gout 659 2,126 0.39 0.98 (0.18) (0.12) 0.38 C , R
Female inflammatory diseases 864 6,331 0.25 0.94 (0.05) (0.03) 0.20
Conjonctivitis 114 6,458 0.24 0.94 (0.01) (0.00) 0.19
Hemorrhoids 1,188 3,048 0.19 0.97 (0.10) (0.06) 0.16
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Table 2 Accuracy of disease detection through drugs prescription among hospitalized patients (N = 108,915) (Continued)
Skin or subcutaneous infections 695 9,565 0.21 0.91 (0.02) (0.01) 0.14
Paludism 28 444 0.14 1.00 0.02 0.01 0.14 28 444 0.14 1.00 (0.02) (0.01) 0.14
Intestinal infectious diseases 1,608 7,131 0.19 0.94 (0.06) (0.03) 0.13
Viral diseases 1,261 1,801 0.15 0.98 (0.11) (0.09) 0.13
Influenza 177 74 0.00 0.00 (0.00)
Multiple diagnoses indication of tracer drugs
Inflammatory polyarthritis and connective tissue disorders 1,321 6,526 0.39 0.94 (0.12) (0.07) 0.35 c
Anaemias – nutritional 3,122 11,845 0.31 0.90 (0.10) (0.06) 0.23 c
Other mental and behavioral disorders 7,852 28,126 0.54 0.76 (0.16) (0.08) 0.37 c
Pain 12,341 66,022 0.73 0.41 (0.07) (0.02) 0.31 c
Severe paind 12,341 7,429 0.16 0.92 (0.13) (0.13) 0.07
Prophylaxis treatment
Tuberculosis 216 226 0.31 1.00 (0.30) (0.29) 0.30
Active tuberculosis 216 82 0.25 1.00 (0.36) (0.66) 0.25 C, R
Alternatives to pharmacological treatment
Neutropenia 468 369 0.18 1.00 (0.21) 0.26 (0.17)
Extended to prophylaxis of myelosuppressive chemotherapy 1,452 369 0.16 1.00 (0.25) 0.63 (0.16) C, R
Obesity 6,106 639 0.03 1.00 (0.05) 0.23 (0.02) c
Other endocrine nutritional and metabolic diseases 8,393 160 0.00 1.00 (0.01) 0.19 (0.00)
Hemorrhagic risk or disease 1,434 756 0.05 0.99 (0.07) 0.09 (0.05)
Poisonings 1,061 309 0.00 1.00 (0.00) 0.00 (0.00)
Heart failure 3,166 94 0.00 1.00 (0.00) 0.02 (0.00)
Alternative refinement: see hypertension/heart failure above
Abuse of tobacco 7,062 14 0.00 1.00 (0.00) 0.08 (0.00)
aKappa values, not used as judgment criteria are in parenthesis.
bContext of use: morbidity indicator (M), ambulatory costs control (C), insurers’ risk adjustment (R) only for chronic conditions.
cAppropriateness of pharmacologic treatment uncertain, prone to practice variations.
dStrong opioids.
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Table 3 Description of morbidity groups
Morbidity groupsa ICD-10 codes ATC codes Codes added + or removed-b
Unmodified diagnostic categories
Tuberculosis (03) A15A19,B90,K230,K673,K930,M011,M490,M900,
N330,N740, N741,O980,P370
J04A J01GA01- J01GB04-
Human immunodeficiency virus disease (05) B20-B24,F024,R75,Z21 J05AE,J05AF,J05AG,J05AR, J05AX07-J05AX09
except J05AF08
J05AF05+
Diabetes mellitus (22) E10-E14,G590,G632,H360, M141,N083,O24 A10
Mental and behavioral disorders due to alcohol (25) F10 N07BB N07BB+
Schizophrenia, schizotypal and delusional disorders (27) F20-F29 N05A , except N05AN N05AD0+ N05AL0+
Mood [affective] disordersc (28) F30-F39 N06A,N06C,N05AN except N06AX01
and N06AX02
Other mental and behavioral disordersd(29) F04-F09,F40-F99 not F803 N05B,N05C,N06B N05BD0+ N05BX0+ N05C + N06B+
Alzheimer’s diseasee (30) F00,G30 N06D not N06DX02
Multiple sclerosis* (31) G35 L03AB02,L03AB07,L03AB08, L03AX13
Epilepsy (32) G40-G41,F803 N03 N03AA0+
Hypertensive disease (38) I10-I15,O10-O11,O13-016 C02,C03 except C03C,C04AB, C07,C08,C09 C04AB + C07 + C08 + C09+
Conduction disorders and cardiac arrhythmias (43) I44-I49 C01A,C01B,C01CA02,C01EB10 C01CA02+
Heart failuref (44) I50 C01CA04, C01CA07,C01CE,C01CX,C03C C01CA04+ C01CX+
Crohn’s disease and ulcerative colitis (65) K50-K51 A07EA,A07EC A07EA+
Infections of the skin and subcutaneous tissue* (77) L01,L02,L08 D06,P03
Hyperplasia of prostate (94) N40 G04BD,G04C G04BD + G04C+
Inflammatory diseases of female pelvic organs* (97) N70-N77, except N740 and N741 G01
Poisoning by drugs and biological substances* (122) T36-T65 V03AB,H04AA01
Subgroups of diagnostic categories
Paludism* (06-) B50-B54 P01B not P01BA02
Parasitosis* (06-) B55-B83, B89 P01A,P01C,P02
Hepatitis B or C (06-) B16-B18 L03AB01,L03AB04,L03AB05,L03AB06,L03AB09,L03AB10,
L03AB11, J05AF08, J05AF10, J05AF11
J05AB04- J05AF05- L03AB01+ L03AB06+
L03AB09+ L03AB11+
Viral diseases* (06-) A60,A80-A99,B00-B15,B19, B25-B34,B941,B942,
B97,J12, J171,J203-J207,J210
J05AA, J05AB, J05AC03, J05AD, J05AX except
J05AX07-J05AX09
Anemia – nutritional* (20-) D50-D53 B03A, B03B
Non nutritional anemia g (20-) D55-64 B03XA
Neutropenia* (21-) D70 L03AA
Thyroid disorders (23-) E00-E07 H03
H
alfon
et
al.BM
C
H
ealth
Services
Research
2013,13:453
Page
8
of
17
http://w
w
w
.biom
edcentral.com
/1472-6963/13/453
Table 3 Description of morbidity groups (Continued)
Other endocrine, nutritional and metabolic
diseases* (23-)
remainder of E00-E90 H01AB, H01AC, H01AX, H01C except H01CB01
Obesity* (23-) E66 A08
Hyperlipidemia (23-) E780-E785 C10
Mental and behavioral disorders due to opioids* (26-) F11,F19 N07BC
Mental and behavioral disorders due to tobacco (26-) F17 N07BA N07BA+
Migraine (34-) G43 N02C N02C+
Parkinson’s disease (34-) G20-G22 N04,except N04BC08 N04BC01+ N04BC06 + h N04BC07+
Conjunctivitis* (36-) H10 S01A, S01GX
Glaucoma (36-) H40, H42 S01E
Eye inflammation* (36-) H00-H05,H11-H16,H20, H22 S01B, S01C
Disorders of external ear* (37-) H601-H609,H62 S02, S03
Vertigo* (37-) H81,H82 N07C
Influenza* (49-) J09-J11 J05AH, J05AC02
Other acute upper respiratory infections* (49-) J00-J06, not J020,J028,J030, J038 R01, R02, R05
Other diseases of upper respiratory tract – allergy (53-) J30,L50 R06, V01 R06 + V01+
Hemorrhoids* (69-) I84, O224, O872 C05A
Functional disorders of the digestive system* (76-) K58, K59 A03, A06, A07DA, A07B, A07CA
Psoriasis (78-) L40 D05, L04AA21, L04AA15 D05 + L04AA21+ L04AA15+
Dermatitis* (78-) L20-L39, not L303 D07, D11AX14, D11AX15
Acne* (79-) L70,L718,L719,L730 D10
Gout (83-) M10 M04A
Osteoporosis (89-) M80-M82 H05, M05BA, M05BB H05 +M05BA +M05BB+
Transplanted organ status (129-) K771,K932,L991,N165,T860, T861-T864,T8681,
T8682,Z94
L04AA02-10, L04AX01, L04AC01, L04AC02 4AD01,
L04AD02
Multiple morbidities groups
Gastroenteritis of presumed infectious origin* (01–02) A00-A09, not A064-A066, K521 A07A, A07F
Ischemic heart diseases (39–41) I20-I25 C01DA, C01DX12, C01DX16 C01DX12+
Reactive airway diseasei (54, 55) J40-J47 R03 R03AA+R03AB+R03BZ+ R03CA+R03CB+
Diseases of esophagus and peptic ulcer (59–61) K20-K31, not K230 and K231 A02BA- A02BD, A02X02
Malignant neoplasm (07–15) C00-C97 A04AA, A04AD12, L01, L02, L03AC01, L03A 3,
L03AX12 L04AX02, V03AF, V03AG, V03AH, 0A,
V10B, V10XX01
L03AA-m A04AD12+ L02+ L03AC01+,
L03AX03+,L03AX12+ L04AX02+ V03AF+
V03AG+V03AH+V10A+V10B+ V10XX01+
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Table 3 Description of morbidity groups (Continued)
Inflammatory polyarthritis and connective tissue
disorders (83,85-)j
M05-M09, M30-M36, M45 H02A, H02B,L04AA13,L04AB01, L04AB04, L04AX03,
M01B, M01CA, M01CB, P01BA02
L04AX03+ M01B +M01CA+
Pain (80-83-,85-88-,111,112-)k M50-M51,M54,R07,R10, R30, R51, R52, remainder
of M60-M79
M01A, M03B, M03C, M09, N02A, N02B M03B +M03C +M09+ N02B+
Mycosis (06-,50-)* B35-B49, J172 D01, J02
Bacterial infection or septicemia* (04,06-,50-,51-,88-) A064-A066, A20-A79 (except A30, A31, A60),
B95,B96, B99, D733, E321, G00, G01, G042,
G060-G062, G07, H600, J020, J028, J030, J038,
remainder of J13-J20, J36, J390, J391, J851-J853,
K046, K047, K1020, K1021, K113, K122, K351, K570,
K572, K574, K578, K61,K630, K750, L00, L03-L05,
M00, M010-M013, M03, M600, M630-M632, M650,
M651; M680, M710, M711, M730, M731, N151, N160,
N340, N412, N450, N459, N751, N764, O85, O911
J01
Thrombo-embolic risk or disease
(34-, 42-,45-,46-,48,101-,102-,106-)l
G08, I260,I269,I2720, I63-I66,I676, I693, I694, I698,
I70, I731,I74, I77, I80-I82, O032, O037, O042, O047,
O052, O057, O062, O067, O072, O077, O082, O223,
O225, O871, O873
B01A
Hemorrhage risk or disease* (21-, 45-,46-) D65-D68, D693-D699 B02,L03AC02
aThe numbers identifying groups are those of the International Shortlist for Hospital Morbidity Tabulation (ISHMT) - Eurostat/OECD/WHO; with dash indicating subgroups. Categories not included in the most recent
RxRisk model18 are indicated with an asterisk*.
bCodes removed or added to those of Kuo et al.14
cThe RxRisk-V distinguishes bipolar disorders (ATC code N05AN) and depression.
dThis category is defined as anxiety and tension in the RxRisk-V (hypnotics not retained as screen).
eThis category is defined as dementia in the RxRisk-V.
fThe RxRisk-V split hypertension in hypertension and congestive heart failure/hypertension, the latter detected by loop diuretics, Angiotensin converting enzyme inhibitors and Angiotensin II receptors blockers.
gDefined as end stage renal disease in the RxRisk-V.
hATC distinguishes, according the dose, the use of the two dopamine agonists bromocryptin and cabergolin N04BC01 , N04BC06: low dose for prolactin inhibition and high dose in parkinsonism.
iAsthma, chronic obstructive pulmonary disease and bronchiectasis.
jRheumatic conditions for original CDS and steroid responsive conditions for Rxrisk.
kThe RxRisk-V distinguishes pain(opioid) from pain and inflammation (NSAI).
lThe RxRisk-V distinguishes anti-platelet from anticoagulant.
mIn our category neutropenia.
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multiple antiepileptic drugs.
Two morbidity groups, for which tracer treatment is
mainly preventive (thromboembolism risk or disease, and
diseases of esophagus/peptic ulcer), had high K1 but very
low K0 (<=0.10). Extending ischemic heart disease and
thrombogenic cardiac arrhythmias to thrombo-embolic
disease increased all Kappa values, suggesting that
secondary prevention is often the treatment aim. En-
hancement in accuracy of peptic disease screening by
removing patients taking a non steroidal anti-inflammatory
(primary prevention hypothesis) was negligible.
Thirty two morbidity categories exhibited poor fit be-
tween diagnoses and drugs. Most of them were acute con-
ditions requiring time-limited drug treatment or minor
conditions seldom occurring or collected in hospitals. We
considered that if such conditions (migraine, mycosis,
acne for instance) had K1 >0.2, they corresponded to an
actual morbidity, but had not been recorded in the
hospital data. However, the uncertainty surrounding the
appropriateness of treatment precluded the adoption of
several groups in spite of fair K1 (see Table 2, last column).
The same limitation prompted cautious use of most cat-
egories detected by tracer drugs that have multiple indi-
cations reaching acceptable K1: hypnotics, painkillers,
nutritional supplements.
At the end of the analysis, 15 morbidity groups were
retained for morbidity indicators (Table 2, letter M), to
which 16 were added for insurers’ risk adjustment (letter
R) and six further groups for ambulatory cost adjustment
(letter C). Twenty three were not retained because of their
poor accuracy or their treatment was prone to practice
variations.
Table 4 shows the reproducibility of drug information
based morbidity categories from one year to the next.
Chronic conditions, for which drug-based information
performed the best were also more reproducible. All
acute conditions had poor reproducibility.
Morbidity prevalence (crude and adjusted) inferred
from 2005 drug information for the whole insured popu-
lation (N = 2,028,620, mean age 55.5, SD age 22.7, men
39.3 percent) are shown in Table 5 and compared with
available national values or estimates from other external
sources. All of our estimates were fairly close to the ref-
erence estimates, with only a few exceptions, Parkinson
and transplants were overestimated (by a factor of 2 and
3 respectively), whereas HIV, Alzheimer’s disease, pros-
tate hyperplasia and osteoporosis were underestimated
by a factor between 2 and 4.
Only 15% of all prescriptions (i.e. a substance identified
by its ATC code delivered to a patient, N = 3,185,997)
were not assigned to a morbidity category; these were
mainly vitamins and other food supplements (20%),
topic medications (36%), vaccines and immune globulinpreparations (10%), contraceptives and hormonal replace-
ment therapy (11%), anesthetics (2%), blood products
and replacement fluids (2%).Discussion
Our drugs-based morbidity groups include the majority
of chronic categories of the most recent CDS derived
tools [12-19]. The few CDS categories our classification
ignored were those deduced from devices or non-
pharmaceutical prescriptions (urinary incontinence, os-
tomy, neurologic bladder, malnutrition), and three with
poor screening (pancreatic insufficiency, hyperkaliemia
and liver failure, the latter removed by other authors
due to different indications of amonemia detoxicants in
many countries) [17]. A few chronic illnesses and
seventeen acute conditions were added. Although we
retained most ATC codes of the revised CDS of Kuo and
al, many drugs were added and some removed [14].
Fifteen chronic conditions (Table 2, M in last column)
exhibited sufficient agreement with their diagnoses-based
counterparts to be considered alternative strategies to
diagnosis for capturing similar populations. Furthermore,
all chronic conditions but four (IBD, mood disorders,
prostate hyperplasia and RAD) exhibited substantial or
almost perfect reliability on test-retest procedure. Finally,
prevalence estimates largely agreed with estimates from
national epidemiological studies whenever prevalence
information is available in Switzerland. Similar age and
gender distribution was found for diabetes [39,40], treated
hyperlipidemia [35,51], treated hypertension [35,52], IBD
[47] and reactive airway disease [38]. Our HIV disease
prevalence agrees with the national estimate of 0.3%, in
view of the fact that 75% of subjects registered in the
Swiss HIV cohort and thus subject to close follow-up
and compulsory treatment receive an antiretroviral ther-
apy [53]. The moderate reproducibility of IBD, mood dis-
orders and RAD may reflect the fact that therapy varies
depending on the severity of conditions like these, which
are characterized by exacerbation and remission periods
[54]. Regarding prostate hypertrophy this may reflect
failed treatment and a switch to surgery [55].
For nine conditions (see Table 2, Ko > 0.4 and indicated
in the last column by C, R), drug-based information
accurately identified only a subset of the population de-
fined by diagnoses. These drugs are often used in a special-
ist care setting (e.g. chronic hepatitis, malignant neoplasm,
multiple sclerosis, neutropenia) and thus might detect
individuals with special or more costly care needs. Most
conditions had only fair or moderate test-retest reliability
reflecting time-limited treatment. Although their ability to
describe the distribution of illnesses is poor, these categor-
ies fit medical conditions sufficiently well to be used to
analyze medical practices and risk adjustment, providing
Table 4 Stability of categories inferred from drugs on patients classified in at least one category in 2005 (N = 410,469)
Morbidity categories Detected in 2005 Detected in 2006 Detected both years K1
Diabetes mellitus 22,530 29,296 0.90 0.90
Transplant 914 1,183 0.88 0.88
Human immunodeficiency virus [HIV] disease 1,057 1,471 0.88 0.88
Multiple sclerosis 353 496 0.84 0.84
Hypertensive disease/heart failure 110,648 136,262 0.87 0.80
Hyperlipidemia 53,593 68,177 0.83 0.80
Glaucoma 9,413 12,019 0.79 0.78
Thrombo-embolic risk or disease 59,070 73,837 0.78 0.73
Osteoporosis 11,272 14,056 0.72 0.71
Thyroid disorders 9,485 11,271 0.70 0.69
Alzheimer’s disease 2,158 2,730 0.69 0.69
Schizophrenia, schizotypal and delusional disorders 12,216 14,522 0.65 0.64
Parkinson’s disease 4,021 4,885 0.64 0.64
Epilepsy 9,290 11,432 0.64 0.63
Malignant neoplasm 5,324 7,553 0.63 0.62
Gout 5,283 6,715 0.62 0.61
Crohn's disease and ulcerative colitis 1,999 2,417 0.59 0.58
Anemia - others 555 801 0.57 0.57
Mood [affective] disorders 52,395 60,280 0.63 0.56
Conduction disorders and cardiac arrhythmias 3,959 4,734 0.56 0.56
Hyperplasia of prostate 12,835 15,751 0.56 0.55
Ischemic heart disease 7,641 7,417 0.49 0.48
Migraine 7,297 7,891 0.49 0.48
Other mental and behavioral disorders 73,679 82,593 0.58 0.47
Other endocrine, nutritional and metabolic diseases 653 778 0.47 0.47
Abuse of opioid 58 74 0.43 0.43
Reactive airway disease 39,237 44,497 0.48 0.42
Diseases of esophagus and peptic ulcer 69,660 83,280 0.52 0.40
Hepatitis B or C 223 260 0.31 0.31
Obesity 1,497 2,196 0.31 0.30
Psoriasis 4,042 4,357 0.31 0.30
Mental and behavioral disorders due to alcohol 979 916 0.29 0.29
Vertigo 5,852 5,523 0.25 0.24
Acne 14,031 15,284 0.27 0.24
Anemia - nutritional 20,758 21,524 0.27 0.22
Functional digestive disorders 69,988 74,141 0.36 0.22
Neutropenia 174 280 0.22 0.22
Inflammatory polyarthritis and connective tissue disorders 12,934 12,965 0.24 0.22
Poisonings 438 763 0.21 0.20
Viral diseases 4,606 5,338 0.20 0.18
Mycosis 51,825 51,635 0.27 0.17
Other diseases of upper respiratory tract - allergy 32,151 32,610 0.23 0.17
Inflammatory diseases of female pelvic organs 17,599 16,556 0.20 0.16
Hemorrhoids 7,991 6,973 0.17 0.16
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Table 4 Stability of categories inferred from drugs on patients classified in at least one category in 2005 (N = 410,469)
(Continued)
Tuberculosis 111 72 0.14 0.14
Eye inflammation 17,078 17,985 0.18 0.14
Dermatitis 49,684 47,769 0.23 0.13
Conjunctivitis 24,435 25,155 0.18 0.13
Abuse of tobacco 53 60 0.09 0.09
Infections of the skin and subcutaneous tissue 29,384 29,508 0.15 0.09
Gastroenteritis of presumed infectious origin 21,755 18,053 0.13 0.09
Hemorrhagic risk or disease 1,476 1,267 0.08 0.08
Disorders of external ear 8,967 7,396 0.08 0.07
Other acute upper respiratory infections 134,478 130,051 0.36 0.06
Paludism 2,270 2,233 0.06 0.06
Parasitosis 5,435 4,718 0.07 0.05
Influenza 314 105 0.02 0.02
Bacterial infection or septicemia 132,933 139,298 0.32 0.00
Pain 235,400 257,672 0.53 0.00
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inpatient diagnoses.
Restricting tuberculosis screening to active cases - i.e.
treated by more than one therapeutic agent - enhanced
accuracy; low sensitivity may be due to time-limited
therapy. However, our estimated prevalence agrees with
the national estimates [50].
For all other conditions, agreement between hospital
diagnoses and drug information was poor, which does
not mean that information inferred from drugs is use-
less. The relationship between drug and diagnoses-based
screening is not straightforward and would benefit by
closer examination. Epilepsy and psychotic disorders
are two examples where diagnoses- based conditions
are much less frequent than drug-based conditions, but
the interpretation is likely to differ. For epilepsy, where
treatment is often continued several years after the last
seizure, many subjects might have treatment renewed
without a coded diagnosis. In such a case, drug-based
information could offer a more complete overview of
the condition. On the other hand, it seems unlikely that
the diagnosis will be overlooked for psychotic disorders.
Because they are used to treat other severe psychiatric
disorders, antipsychotic drugs cannot be consistently
associated with overlooked psychotic disorders.
Categories in which drug information detects a greater
number of conditions than diagnosis pose a particular
problem, since therapy might more effectively reflect
medical practices than true conditions. For instance,
primary prevention of peptic ulcer by means of nonste-
roidal anti-inflammatory drugs does not provide evi-
dence of an active disease, and therapy for functional
dyspepsia may be disputable. If the acute nature of bacterialinfection may explain the poor fit between diagnoses
and drug-based information, the fact that antibiotherapy
is often prescribed inappropriately is an important as-
pect when considering pharmacy-based screening. The
high prevalence of other broadly defined conditions, e.g.,
pain, certain mental and behavioral disorders may also
highlight their overestimation.
While some drugs-based morbidity groups were very
specific (i.e. tuberculosis, vertigo, psoriasis, neutropenia),
others were broad (viral diseases, malignant neoplasms).
For the latter, more accurate information could be obtained
from other data sources, including cancer registries. Miss-
ing information due to hospital drug dispensation might
also explain the poor sensitivity of malignant neoplasm.
The most widespread application of disease status meas-
ure computable from routinely available data is to correct
for confounding when comparing health care service
indicators. Which rate of error is tolerable when esti-
mating a population’s health from drugs dispensation
depends on the purpose of the indicator [1]. Morbidity
indicators require satisfactory agreement between drugs-
based and diagnoses categories (see Table 2). The basis
of this interpretation is the Kappa thresholds defined by
the authors. Only 15 categories fit this purpose. For
other indicators, such a stringent criterion is not re-
quired. Inpatient diagnoses have limited pertinence, as
only a minority of enrollees is hospitalized, particularly
under age 65. Consequently, some data are better than
none, but only if the measure creates no perverse incen-
tives. Several categories that reflect medical practices ra-
ther than true morbidity must be viewed with caution,
even when they have good predictive performance (over-
use of medication).
Table 5 2005 estimated prevalence of illness inferred from drugs’ dispensation among 2,028,621 insured
Morbidity categories Crude rates (%) Gender and age adjusted
rates (%)
Published prevalence
rates (%)b
Pain 31.6 31.4
Other acute upper respiratory infections 18.1 18.2
Bacterial infection or septicemia 17.5 17.4
Hypertensive disease/heart failure 14.9 19.0 Aged 35–75: 36.7, 50.1% currently treated [35]
Mental disorders 14.1 14.1 Aged 18–65: 26.0 -28.3 [36]
Other mental and behavioral disorders 10.1 9.3
Mood [affective] disorders 7.5 8.3 Major depression: 2-7 [36,37]
Schizophrenia, schizotypal and delusional disorders 1.7 1.8 0.2–1.3 [36,37]
Diseases of esophagus and peptic ulcer 9.4 9.1
Functional digestive disorders 9.2 9.0
Thrombo-embolic risk or disease 7.9 7.4
Mycosis 7.2 7.1
Hyperlipidemia 7.3 10.8 Aged 35–75 treated: 13.5 [35]
Dermatitis 6.4 6.3
Other diseases of upper respiratory tract - allergy 5.3 5.4
Reactive airway disease 5.4 5.6 Aged > 29: 5.0 [38]
Infections of the skin and subcutaneous tissue 3.9 3.9
Conjunctivitis 3.2 3.3
Diabetes mellitus 3.1 3.8 Aged >19: 3.5-4.3 [39,40]
Gastroenteritis of presumed infectious origin 2.8 2.8
Anemia - nutritional 2.6 2.5
Inflammatory diseases of female pelvic organs 2.5 2.5
Eye inflammation 2.1 2.1
Hyperplasia of prostate 2.2 5.2 Males > 39: 13-28 [41],a
Acne 1.8 1.9
Inflammatory polyarthritis and connective tissue disorders 1.7 1.6
Glaucoma 1.6 2.9 Aged > 39: 2 [42],a
Osteoporosis 1.5 3.3 Aged > 39: 13.8 [43]
Epilepsy 1.3 1.3 1.0 [44],a
Thyroid disorders 1.2 1.2 1.0 [45],a
Disorders of external ear 1.1 1.1
Hemorrhoids 1.0 1.0
Migraine 0.99 0.98
Ischemic heart disease 0.99 0.89
Malignant neoplasm 0.74 0.71
Vertigo 0.73 0.70
Parasitosis 0.68 0.68
Gout 0.70 0.66
Viral diseases 0.61 0.60
Psoriasis 0.53 0.52
Parkinson’s disease 0.54 1.68 Aged > 59: 0.91 [46]
Conduction disorders and cardiac arrhythmias 0.52 0.47
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Table 5 2005 estimated prevalence of illness inferred from drugs’ dispensation among 2,028,621 insured (Continued)
Paludism 0.29 0.29
Alzheimer's disease 0.30 1.26 Aged > 59: 4.5 [46]
Crohn's disease and ulcerative colitis 0.27 0.26 0.21 [47]
Hemorrhagic risk or disease 0.19 0.24
Obesity 0.22 0.21
Human immunodeficiency virus [HIV] disease 0.15 0.14 0.3 [48]
Transplant 0.12 0.12 Renal grafts only ~0.04 [49],b
Mental and behavioral disorders due to alcohol 0.12 0.12
Other endocrine, nutritional and metabolic diseases 0.09 0.09
Anemia - others 0.08 0.08
Poisonings by drugs, medication and biological substances
and toxic effects of substances chiefly nonmedicinal
0.06 0.06
Multiple sclerosis 0.05 0.05
Influenza 0.04 0.04
Hepatitis B or C 0.03 0.03
Neutropenia 0.03 0.02
Tuberculosis (active) 0.01 0.01 0.008 [50]
Abuse of opioids 0.01 0.01
aInternational data due to lack of Swiss data.
bConsidering 250 transplants per year between 1998 and 2006, and a graft half-life of 13 years.
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the validation of drug-based classification to inpatients,
thus underestimating specificity by under-reporting chronic
co-morbidities. On the other hand, sensitivity is measured
on a population suffering from more severe conditions
and might be overestimated. There might be variations
in the hospital coding practices across countries due to
differences in coding rules, coding purposes such as
hospital payment or the thoroughness of secondary diag-
nosis coding, which is sometimes limited by the data
fields available. Therefore, caution should be exercised
when generalizing our results to other countries. Some
conditions, mainly those treated in ambulatory settings,
are poorly represented. Further studies conducted in
ambulatory settings might rate drugs-based acute or
milder categories differently. Another problem is that
we may be identifying incidental users of a drug rather
than a real condition; for example, having been treated
by a proton-pump inhibitor or a painkiller does not mean
having a disease.
Conclusion
We defined sixty morbidity categories that may in theory
be related to a particular drug signature that might be
applied internationally. Drug information was a good
proxy of diagnoses to identify 15 chronic conditions, pro-
viding useful information for epidemiological studies.
Although the accuracy of detection was only fair,
twenty-two other morbidities could also be exploitedfor health insurers’ risk adjustment or ambulatory cost
control. Several categories were excluded because they
prone to variations in prescribing (pain, bacterial infec-
tion, peptic ulcer). Some acute diseases poorly repre-
sented in hospitalized populations should be studied
further on outpatient samples. Further research should
also focus on more detailed validation, e.g. using med-
ical records or other more precise data.
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